Patient Engagement

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.

Key trends in healthcare communication to build trust between healthcare providers and their patients.

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer of Pleio, discusses the significant threat of misinformation to public health and how emotional appeal plays a part.

In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

How one Big Pharma ad campaign is incorporating diversity as a driving force in improving the ways drugs are marketed directly to the patients that need them.

The benefits for brand teams in bolstering their rapid-response capability.

In this part of his Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, identifies strategies pharmaceutical companies can use to combat misinformation on social media.

In this Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, speaks about how distrust and uncertainty surrounding social media is impacting the pharmaceutical industry.

In this Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, identifies how uncertainty of where to find information, coupled with distrust, can damage the relationship between pharmaceutical companies and the patients they aim to serve.

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

In this part of his Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, explores the contributing factors growing distrust and uncertainty surrounding social media.

With increasing cases of disinformation across social media blurring the lines of what’s credible and real, how can pharma break through the noise and build back public trust?

How alternative direct-to-consumer models are changing the landscape for patient access.

AI provides opportunities to bring people together—not replace them.

In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, identifies which metrics and KPIs can be used to measure the effectiveness of AI-powered patient engagement and adherence programs.

In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, discusses how pharmaceutical companies navigate the evolving regulatory landscape to ensure that AI-powered interventions comply with relevant regulations and guidelines.

In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, explores the ethical implications of using AI to collect and analyze patient data, and improve outcomes.

In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, identifies how AI can identify patients at risk of medication non-adherence and intervene early to prevent negative outcomes.

In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, explains how AI can be leveraged to create highly personalized patient engagement strategies, tailored to individual needs and preferences.

Webinar Date/Time: Wed, Oct 16, 2024 2:00 PM EDT

The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.

As the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?